Emerging drugs for renal cell carcinoma

被引：5
作者：
Varella, Leticia [1 ]
Rini, Brian I. [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA
来源：
EXPERT OPINION ON EMERGING DRUGS | 2010年 / 15卷 / 03期
关键词：
novel agents; renal cell carcinoma; targeted therapy; VEGF; ENDOTHELIAL GROWTH-FACTOR; DOSE RECOMBINANT INTERLEUKIN-2; TYROSINE KINASE INHIBITOR; RANDOMIZED PHASE-II; INTERFERON-ALPHA; MONOCLONAL-ANTIBODY; FACTOR RECEPTOR; ANTITUMOR ACTIVITIES; SELECTIVE INHIBITOR; MAMMALIAN TARGET;
D O I：
10.1517/14728214.2010.486788
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Importance of the field: The treatment of metastatic renal cell carcinoma (RCC) has evolved significantly over the past 5 years and targeted therapy has become the standard of care. However, complete and lasting responses to these drugs are still uncommon. Currently, novel agents are being tested in clinical trials. Areas covered in this review: We discuss approved targeted agents in RCC and emphasize on emerging therapies. We searched the US National Library of Medicine (PubMed) using the terms 'renal cell carcinoma', 'targeted therapy' and 'novel agents', from 1990 to the present. We also searched for abstracts from the meetings of the American Society of Clinical Oncology and Genitourinary Cancers Symposium from 2007 to the present. What the reader will gain: This paper provides understanding of the approved treatments for advanced RCC as well as the novel agents and their targeted biological pathways. Take home message: Despite dynamic and recent advances in the management of metastatic RCC much about the molecular biology of this tumor has yet to be delineated. Even more so, strategies of sequential treatment, combination of targeted drugs, mechanisms of resistance, optimal dosages and scheduling remain areas of potential development interest.
引用
收藏
页码：343 / 353
页数：11
相关论文
共 53 条
[1]   A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer [J].
Amato, Robert J. ;
Jac, Jaroslaw ;
Giessinger, Sarah ;
Saxena, Somyata ;
Willis, James P. .
CANCER, 2009, 115 (11) :2438-2446
[2]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[3]  
Bhargava P, 2009, J CLIN ONCOL, V27
[4]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[5]   RETRACTED: Immunotherapy for advanced renal cell cancer - art. no. CD001425.pub2 (Retracted Article) [J].
Coppin, C ;
Porzsolt, F ;
Awa, A ;
Kumpf, J ;
Coldman, A ;
Wilt, T .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)
[6]   Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer [J].
Di Lorenzo, Giuseppe ;
Carteni, Giacomo ;
Autorino, Riccardo ;
Bruni, Gianni ;
Tudini, Marianna ;
Rizzo, Mimma ;
Aieta, Michele ;
Gonnella, Antonio ;
Rescigno, Pasquale ;
Perdona, Sisto ;
Giannarini, Gianluca ;
Pignata, Sandro ;
Longo, Nicola ;
Palmieri, Giovannella ;
Imbimbo, Ciro ;
De Laurentiis, Michele ;
Mirone, Vincenzo ;
Ficorella, Corrado ;
De Placido, Sabino .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4469-4474
[7]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[8]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[9]   Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma [J].
Escudier, Bernard ;
Szczylik, Cezary ;
Hutson, Thomas E. ;
Demkow, Tomasz ;
Staehler, Michael ;
Rolland, Frederic ;
Negrier, Sylvie ;
Laferriere, Nicole ;
Scheuring, Urban J. ;
Cella, David ;
Shah, Sonalee ;
Bukowski, Ronald M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1280-1289
[10]  
Fisher RI, 2000, CANCER J SCI AM, V6, pS55
123456